Annual CFI
$119.88 M
+$272.60 M+178.50%
December 31, 2023
Summary
- As of February 8, 2025, MRSN annual cash flow from investing activities is $119.88 million, with the most recent change of +$272.60 million (+178.50%) on December 31, 2023.
- During the last 3 years, MRSN annual CFI has risen by +$82.86 million (+223.77%).
- MRSN annual CFI is now at all-time high.
Performance
MRSN Cash From Investing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly CFI
$28.47 M
+$22.96 M+416.32%
September 30, 2024
Summary
- As of February 8, 2025, MRSN quarterly cash flow from investing activities is $28.47 million, with the most recent change of +$22.96 million (+416.32%) on September 30, 2024.
- Over the past year, MRSN quarterly CFI has dropped by -$75.31 million (-72.57%).
- MRSN quarterly CFI is now -72.57% below its all-time high of $103.78 million, reached on September 30, 2023.
Performance
MRSN Quarterly CFI Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM CFI
-$18.41 M
-$75.31 M-132.37%
September 30, 2024
Summary
- As of February 8, 2025, MRSN TTM cash flow from investing activities is -$18.41 million, with the most recent change of -$75.31 million (-132.37%) on September 30, 2024.
- Over the past year, MRSN TTM CFI has dropped by -$72.72 million (-133.91%).
- MRSN TTM CFI is now -115.36% below its all-time high of $119.88 million, reached on December 31, 2023.
Performance
MRSN TTM CFI Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash From Investing Formula
CFI = Cash Inflows from Investments − Cash Outflows for Investments
MRSN Cash From Investing Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +178.5% | -72.6% | -133.9% |
| 3 y3 years | +223.8% | -72.6% | -133.9% |
| 5 y5 years | +37.5% | -72.6% | -133.9% |
MRSN Cash From Investing Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | at high | +178.5% | -72.6% | +131.5% | -115.4% | +87.9% |
| 5 y | 5-year | at high | +178.5% | -72.6% | +131.5% | -115.4% | +87.9% |
| alltime | all time | at high | +178.5% | -72.6% | +131.5% | -115.4% | +87.9% |
Mersana Therapeutics Cash From Investing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | $28.47 M(+416.3%) | -$18.41 M(-132.4%) |
| Jun 2024 | - | $5.51 M(-107.6%) | $56.89 M(+23.8%) |
| Mar 2024 | - | -$72.55 M(-460.1%) | $45.94 M(-61.7%) |
| Dec 2023 | $119.88 M(-178.5%) | $20.15 M(-80.6%) | $119.88 M(+120.7%) |
| Sep 2023 | - | $103.78 M(-2008.0%) | $54.31 M(-182.3%) |
| Jun 2023 | - | -$5.44 M(-489.6%) | -$65.96 M(-56.3%) |
| Mar 2023 | - | $1.40 M(-103.1%) | -$150.99 M(-1.1%) |
| Dec 2022 | -$152.72 M(>+9900.0%) | -$45.43 M(+175.5%) | -$152.72 M(+42.1%) |
| Sep 2022 | - | -$16.49 M(-81.8%) | -$107.44 M(+18.1%) |
| Jun 2022 | - | -$90.47 M(>+9900.0%) | -$91.00 M(>+9900.0%) |
| Mar 2022 | - | -$329.00 K(+112.3%) | -$863.00 K(+33.2%) |
| Dec 2021 | -$648.00 K(-101.8%) | -$155.00 K(+237.0%) | -$648.00 K(-4.8%) |
| Sep 2021 | - | -$46.00 K(-86.2%) | -$681.00 K(-131.4%) |
| Jun 2021 | - | -$333.00 K(+192.1%) | $2.17 M(-87.6%) |
| Mar 2021 | - | -$114.00 K(-39.4%) | $17.48 M(-52.8%) |
| Dec 2020 | $37.03 M | -$188.00 K(-106.7%) | $37.03 M(-31.1%) |
| Sep 2020 | - | $2.81 M(-81.3%) | $53.72 M(+487.6%) |
| Jun 2020 | - | $14.97 M(-22.9%) | $9.14 M(-150.8%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2020 | - | $19.43 M(+17.8%) | -$17.99 M(-34.1%) |
| Dec 2019 | -$27.29 M(-131.3%) | $16.50 M(-139.5%) | -$27.29 M(-9.2%) |
| Sep 2019 | - | -$41.77 M(+243.7%) | -$30.07 M(-192.7%) |
| Jun 2019 | - | -$12.15 M(-220.0%) | $32.42 M(-56.4%) |
| Mar 2019 | - | $10.13 M(-26.2%) | $74.42 M(-14.6%) |
| Dec 2018 | $87.19 M(-187.5%) | $13.72 M(-33.8%) | $87.19 M(+44.6%) |
| Sep 2018 | - | $20.73 M(-30.6%) | $60.28 M(-2722.1%) |
| Jun 2018 | - | $29.85 M(+30.3%) | -$2.30 M(-97.0%) |
| Mar 2018 | - | $22.90 M(-273.6%) | -$76.25 M(-23.5%) |
| Dec 2017 | -$99.62 M(+9090.4%) | -$13.19 M(-68.5%) | -$99.62 M(+15.6%) |
| Sep 2017 | - | -$41.85 M(-5.1%) | -$86.18 M(+94.2%) |
| Jun 2017 | - | -$44.11 M(+9265.0%) | -$44.39 M(+3726.4%) |
| Mar 2017 | - | -$471.00 K(-285.4%) | -$1.16 M(+7.0%) |
| Dec 2016 | -$1.08 M(+38.4%) | $254.00 K(-523.3%) | -$1.08 M(-19.0%) |
| Sep 2016 | - | -$60.00 K(-93.2%) | -$1.34 M(+4.7%) |
| Jun 2016 | - | -$883.00 K(+123.5%) | -$1.28 M(+223.5%) |
| Mar 2016 | - | -$395.00 K | -$395.00 K |
| Dec 2015 | -$783.00 K | - | - |
FAQ
- What is Mersana Therapeutics annual cash flow from investing activities?
- What is the all time high annual CFI for Mersana Therapeutics?
- What is Mersana Therapeutics annual CFI year-on-year change?
- What is Mersana Therapeutics quarterly cash flow from investing activities?
- What is the all time high quarterly CFI for Mersana Therapeutics?
- What is Mersana Therapeutics quarterly CFI year-on-year change?
- What is Mersana Therapeutics TTM cash flow from investing activities?
- What is the all time high TTM CFI for Mersana Therapeutics?
- What is Mersana Therapeutics TTM CFI year-on-year change?
What is Mersana Therapeutics annual cash flow from investing activities?
The current annual CFI of MRSN is $119.88 M
What is the all time high annual CFI for Mersana Therapeutics?
Mersana Therapeutics all-time high annual cash flow from investing activities is $119.88 M
What is Mersana Therapeutics annual CFI year-on-year change?
Over the past year, MRSN annual cash flow from investing activities has changed by +$272.60 M (+178.50%)
What is Mersana Therapeutics quarterly cash flow from investing activities?
The current quarterly CFI of MRSN is $28.47 M
What is the all time high quarterly CFI for Mersana Therapeutics?
Mersana Therapeutics all-time high quarterly cash flow from investing activities is $103.78 M
What is Mersana Therapeutics quarterly CFI year-on-year change?
Over the past year, MRSN quarterly cash flow from investing activities has changed by -$75.31 M (-72.57%)
What is Mersana Therapeutics TTM cash flow from investing activities?
The current TTM CFI of MRSN is -$18.41 M
What is the all time high TTM CFI for Mersana Therapeutics?
Mersana Therapeutics all-time high TTM cash flow from investing activities is $119.88 M
What is Mersana Therapeutics TTM CFI year-on-year change?
Over the past year, MRSN TTM cash flow from investing activities has changed by -$72.72 M (-133.91%)